Target Price | $314.91 |
Price | $285.98 |
Potential | 10.12% |
Number of Estimates | 22 |
22 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $314.91. This is 10.12% higher than the current stock price. The highest price target is $408.00 42.67% , the lowest is $185.00 35.31% . | |
A rating was issued by 31 analysts: 14 Analysts recommend Amgen to buy, 14 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 10.12% . Most analysts recommend the Amgen stock at Buy or hold. |
25 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $35.2b . This is 5.81% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $35.9b 8.08% , the lowest is $34.6b 4.18% .
This results in the following potential growth metrics:
2024 | $33.2b | 18.64% |
---|---|---|
2025 | $35.2b | 5.81% |
2026 | $36.0b | 2.42% |
2027 | $37.0b | 2.66% |
2028 | $36.8b | 0.35% |
2029 | $38.2b | 3.63% |
10 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $18.0b . This is 26.00% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $21.4b 49.41% , the lowest is $14.0b 2.01% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $13.9b | 12.54% |
---|---|---|
2025 | $18.0b | 29.75% |
2026 | $18.2b | 0.75% |
2027 | $18.5b | 1.85% |
2028 | $18.6b | 0.68% |
2029 | $18.6b | 0.04% |
2024 | 41.84% | 5.15% |
---|---|---|
2025 | 51.31% | 22.63% |
2026 | 50.47% | 1.64% |
2027 | 50.07% | 0.79% |
2028 | 50.59% | 1.04% |
2029 | 48.80% | 3.54% |
8 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $6.2b . This is 51.94% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $7.8b 92.85% , the lowest is $4.3b 7.02% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.47% |
---|---|---|
2025 | $6.2b | 51.74% |
2026 | $7.0b | 13.96% |
2027 | $8.9b | 27.36% |
2028 | $9.2b | 3.13% |
2029 | $11.1b | 20.62% |
2024 | 12.21% | 48.98% |
---|---|---|
2025 | 17.52% | 43.44% |
2026 | 19.49% | 11.24% |
2027 | 24.18% | 24.06% |
2028 | 25.02% | 3.47% |
2029 | 29.13% | 16.43% |
8 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $11.47 . This is 51.92% higher than earnings per share in the financial year 2024. The highest EPS forecast is $14.56 92.85% , the lowest is $8.08 7.02% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $11.47 | 51.72% |
2026 | $13.07 | 13.95% |
2027 | $16.65 | 27.39% |
2028 | $17.17 | 3.12% |
2029 | $20.71 | 20.62% |
Current | 37.90 | 75.30% |
---|---|---|
2025 | 24.93 | 34.22% |
2026 | 21.88 | 12.23% |
2027 | 17.18 | 21.48% |
2028 | 16.65 | 3.08% |
2029 | 13.81 | 17.06% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.76 and an P/S ratio of 4.37 .
This results in the following potential growth metrics and future valuations:
Current | 6.09 | 14.35% |
---|---|---|
2025 | 5.76 | 5.42% |
2026 | 5.62 | 2.36% |
2027 | 5.48 | 2.59% |
2028 | 5.50 | 0.35% |
2029 | 5.30 | 3.50% |
Current | 4.62 | 10.49% |
---|---|---|
2025 | 4.37 | 5.49% |
2026 | 4.27 | 2.36% |
2027 | 4.16 | 2.59% |
2028 | 4.17 | 0.35% |
2029 | 4.02 | 3.50% |
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 09 2025 |
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Mar 05 2025 |
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Feb 10 2025 |
B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Feb 06 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Jan 28 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jan 24 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jan 10 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 09 2025 |
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Mar 05 2025 |
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Feb 10 2025 |
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Feb 06 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Jan 28 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jan 24 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Jan 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.